We performed survival analysis using the TCGA PAAD cohort for each of these genes and found statistically significant differences in twenty-eight genes (IFI27, IL1R2, IL1RN, IL1RAP, IL18, IL22RA1, HCP5, SLFN13, CD58, CD109, IFI44L, IFI16, IFITM1, IFIT1, IFIT3, IRF9, IFIT2, IFI35, CXCL10, CXCL5, CXCL9, S100P, S100A6, S100A2, S100A16, S100A11, S100A14, and S100A10), which shared a pattern: a higher expression in patients associated with a lower rate of survival. This evidence concerns the gene IL22RA1 and pancreatic adenocarcinoma.